N@N

Lpath, Inc.: Lpath to Present at the 2009 BIOCOM Investor Conference

_{//health-fitness.news-articles.net/content/2009/ .. sent-at-the-2009-biocom-investor-conference.html}
^{Published in Health and Fitness on Friday, October 23rd 2009 at 5:39 GMT by Market Wire}  

SAN DIEGO, CA--(Marketwire - October 23, 2009) - Lpath, Inc. (OTCBB: [ LPTN ]), the category leader in therapeutic agents against bioactive lipids, will present at the 2009 BIOCOM Investor Conference, which will be held October 26-27, 2009 at the Hyatt Regency La Jolla in San Diego, California.

Lpath president and CEO Scott R. Pancoast is scheduled to present on Monday, October 26th at 11:00 a.m. Pacific time (2:00 p.m. Eastern time), followed by a break-out Q&A session and one-on-one meetings.

As part of his presentation, Pancoast will present the recent clinical results from one of the company's leading drug candidates, iSONEP™, which was well tolerated at all dose levels in a Phase 1 trial in wet-AMD patients. As previously disclosed in the company's October 8, 2009 press release, many of the patients exhibited positive biological effects largely independent of the effects seen when wet-AMD patients undergo treatment with currently approved therapies.

The presentation will be available via live webcast and replay at: [ http://cc.talkpoint.com/bcom001/102609a_me/?entity=19_12XEB52 ]

For more information on the BIOCOM Investor Conference, please visit the conference website at [ www.biocom.org/event/2009_Investor_Conference ].

About Lpath
San Diego-based Lpath, Inc. is the category leader in lipidomics-based therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company is currently advancing three drug candidates, two of which -- ASONEP™ for cancer and iSONEP™ for AMD -- are nearing completion of Phase 1 clinical trials. With ASONEP, Lpath has joined with Merck Serono under a worldwide exclusive license and development partnership. For more information, go to [ www.Lpath.com ].